Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Arpita Gandhi, Rasmus T. Hoeg, Sagar S. Patel, Edmund K. Waller, Jeremy M. Pantin, Caspian H. Oliai, J. Scott McClellan, Anna Pavlova, Irene Agodoa, Nathaniel B. Fernhoff, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2023-188994

Published: 2023

Journal Articles

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Richard T. Maziarz, Steven M Devine, Louis P. Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin, Miguel-Angel Perales

Blood (2022) 140 (Supplement 1): 10833–10834.

https://doi.org/10.1182/blood-2022-157439

Published: 2022

Journal Articles

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

R. Clark Clark Brown, Andrew Redfern, Eleanor Lisbon, Carla Washington, Irene Agodoa, Kim Smith-Whitley

Blood (2021) 138 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2021-152924

Published: 2021

Journal Articles

The Role of Hemoglobin and Hemolysis on Transcranial Doppler Velocities in Children with Sickle Cell Disease: Data from a Natural History Cohort

Giulia Reggiani, Beatrice Coppadoro, Vania Munaretto, Renzo Manara, Claudio Baracchini, Alessio Pieroni, Federica Viaro, Irene Agodoa, Anne Beaubrun, Alessandra Biffi, Laura Sainati, Raffaella Colombatti

Blood (2021) 138 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2021-148043

Published: 2021

Journal Articles

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Nirmish Shah, Thokozeni Lipato, Ofelia A. Alvarez, Thomas Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Irene Agodoa

Blood (2021) 138 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2021-153138

Published: 2021

Journal Articles

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Ahmar Urooj Zaidi, MD, Thokozeni Lipato, MD, Ofelia A. Alvarez, MD, Alexander Lonshteyn, PhD, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD, Nirmish Shah, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140525

Published: 2020

Journal Articles

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

William B Ershler, MD, Laura M De Castro, MD MHSc, Zahra Pakbaz, MD, Aaron Moynahan, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140572

Published: 2020

Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-140553

Published: 2020

Journal Articles

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Elliott Vichinsky, MD, Victor R. Gordeuk, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD FAAP, Margaret Tonda, PharmD, Sarah Gray, PhD, Irene Agodoa, MD, Kenneth I. Ataga, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140863

Published: 2020

Journal Articles

Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study

Jeremie H. Estepp, MD, Ze Cong, PhD, Irene Agodoa, MD, Guolian Kang, PhD, Juan Ding, PhD, M. Beth McCarville, MD, Jane S. Hankins, MD MS, Winfred Wang, MD

Blood (2019) 134 (Supplement_1): 1002.

https://doi.org/10.1182/blood-2019-131177

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Elizabeth Williams, BA, Elizabeth Brown, Deepa Manwani, MD, Payal Desai, MD, Joshua J. Field, MD, Lynne D. Neumayr, Susan Padrino, MD, E. Leila Jerome Clay, MD MCTS, FAAP, Ze Cong, PhD, Irene Agodoa, MD, Carolyn Hoppe, MD, Sophie M. Lanzkron, MD, Jane A. Little, MD

Blood (2019) 134 (Supplement_1): 2284.

https://doi.org/10.1182/blood-2019-124933

Published: 2019

Journal Articles

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Xue Song, Andrew D. Campbell, MD, Ze Cong, PhD, Irene Agodoa, MD, Diane Martinez, DrPH, MPH, Carolyn R. Lew, PhD, Danae Black, Helen Varker, Chris Chan, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 3388.

https://doi.org/10.1182/blood-2019-127173

Published: 2019

Journal Articles

Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Estimated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis

Kenneth I. Ataga, MBBS, Victor R. Gordeuk, MD, I. Elaine Allen, PhD, Jennifer Colby, PharmD, Kimberly Gittings, PharmD, Irene Agodoa, MD

Blood (2018) 132 (Supplement 1): 12.

https://doi.org/10.1182/blood-2018-99-117261

Published: 2018

Journal Articles

Societal Costs of Sickle Cell Disease in the United States

Irene Agodoa, MD, Deborah Lubeck, PhD, Nickhill Bhakta, MD MPH, Mark Danese, MHS, PhD, Kartik Pappu, PhD, Robin Howard, MBA, Michelle Gleeson, PhD, Marc Halperin, BA, Sophie Lanzkron, MD MHS

Blood (2018) 132 (Supplement 1): 4706.

https://doi.org/10.1182/blood-2018-99-119420

Published: 2018

Journal Articles

Opioid Utilization Patterns in United States Patients with Sickle Cell Disease

Samir K. Ballas, MD, Julie Kanter, MD, Irene Agodoa, MD, Robin Howard, Sally Wade, Virginia Noxon, PhD, Carlton Dampier, MD

Blood (2017) 130 (Supplement 1): 130.

https://doi.org/10.1182/blood.V130.Suppl_1.130.130

Published: 2017

Journal Articles

Quality of Care in United States Children with Sickle Cell Anemia

Julie Kanter, MD, Carlton Dampier, MD, Irene Agodoa, MD, Robin Howard, Sally Wade, Virginia Noxon, PhD, Samir K. Ballas, MD

Blood (2017) 130 (Supplement 1): 2098.

https://doi.org/10.1182/blood.V130.Suppl_1.2098.2098

Published: 2017

Journal Articles

Access to Care for Medicaid and Commercially-Insured United States Patients with Sickle Cell Disease

Carlton Dampier, MD, Julie Kanter, MD, Robin Howard, Irene Agodoa, MD, Sally Wade, Virginia Noxon, PhD, Samir K. Ballas, MD

Blood (2017) 130 (Supplement 1): 4660.

https://doi.org/10.1182/blood.V130.Suppl_1.4660.4660

Published: 2017

Journal Articles

Impact of GBT440 on Unconjugated Bilirubin and Jaundice in Sickle Cell Disease: A Patient Case Report

Paul Telfer, FRCPath, MD, Josh Lehrer, MD MPhil, FACC, Irene Agodoa, MD, Marzena Jurek, MS, Kathleen M Fox, PhD, Laurie Burke, BPharm, MPH, Noel Landsman, Dip.Nur (SA), Timothy Mant, MB, FFPM, FRCP

Blood (2017) 130 (Supplement 1): 4779.

https://doi.org/10.1182/blood.V130.Suppl_1.4779.4779

Published: 2017

NARROW

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

The Role of Hemoglobin and Hemolysis on Transcranial Doppler Velocities in Children with Sickle Cell Disease: Data from a Natural History Cohort

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Estimated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis

Societal Costs of Sickle Cell Disease in the United States

Opioid Utilization Patterns in United States Patients with Sickle Cell Disease

Quality of Care in United States Children with Sickle Cell Anemia

Access to Care for Medicaid and Commercially-Insured United States Patients with Sickle Cell Disease

Impact of GBT440 on Unconjugated Bilirubin and Jaundice in Sickle Cell Disease: A Patient Case Report

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only